

Special Issue

Pharmacogenomics: Current Status and Future Perspectives

Message from the Guest Editor

The purpose of this Special Issue, “Pharmacogenomics: Current Status and Future Perspectives”, is two-fold: (1) to shed light on the progress made in the last years in the Pharmacogenetics and Pharmacogenomics field and on its future challenges to provide a thorough overview of the state of the art in this area of research, and (2) to focus on new insights, novel developments, current challenges, latest discoveries, recent advances and future perspectives in this field. This Special Issue aims to collect articles to increase the knowledge in the pharmacogenetics area and its implementation in the clinical setting. In this Special Issue, original research articles and reviews are welcome. Research areas may include the following: pharmacogenetics, clinical implementation of pharmacogenetics and identification of genetic factors associated with drug responses in clinical setting, between others. I would like to invite you, experts and beginners in the field of pharmacogenomics, to contribute to this Special Issue with your research, in order to accelerate the implementation of pharmacogenomic procedures in drug development and clinical practice.

Guest Editor

Dr. Marta Miarons Font

Hospital Universitari Vall d'Hebron, Barcelona, Spain

Deadline for manuscript submissions

closed (5 February 2024)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/181451

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).